Teicoplanin (formerly teichomycin A2) is a complex of glycopeptide antibiotics related to vancomycin and ristocetin. The major components have molecular weights of about 1,900 (2) . Teicoplanin interferes with cell wall synthesis by inhibiting polymerization of peptidoglycans (9) . Like vancomycin, teicoplanin is bactericidal against grampositive microorganisms (7, 8) . It is approximately twice as active as vancomycin against Staphylococcus spp., including methicillin-resistant strains, and is distinctly more active than vancomycin against streptococci, including the enterococci (1, 3, 7, 8, 10) . Teicoplanin is also active against the JK group of corynebacteria (4, 7), Listeria monocytogenes (7), and anaerobic, gram-positive bacteria (8) . Fusidic acid and coumermycin are two other antimicrobial agents with similar spectrums of activity largely limited to gram-positive bacteria, especially methicillin-resistant and -susceptible staphylococci.
The purpose of this report is to describe our efforts to evaluate teicoplanin disk susceptibility tests and to reevaluate vancomycin disk test interpretive standards. In vitro data comparing teicoplanin with vancomycin, fusidic acid, and coumermycin are also reported. 
MATERIALS AND METHODS

Antibiotics
RESULTS
In vitro activity. Table 1 summarizes the results of the microdilution tests with gram-positive microorganisms. All four drugs were inactive against the 24 representative gramnegative bacilli that were tested (data not shown). Against the staphylococci, teicoplanin was two to four times more active than vancomycin. Fusidic acid was 2 to 4 times more active than teicoplanin, and coumermycin was about 16 times more active than fusidic acid. Against the streptococci, teicoplanin was the most active compound, and fusidic acid was the least active drug that was tested. All four drugs effectively inhibited the JK group of corynebacteria.
Disk diffusion tests. The effect of increasing the potency of teicoplanin disks is described by the data in Table 2 . Although teicoplanin was more active than vancomycin, 30-jig teicoplanin disks produced zones 1 to 2 mm smaller than those around 30-jig vancomycin disks. For each twofold Figure 1 displays the results of tests with 30-jig teicoplanin disks. Interpretive breakpoints of '10 and -14 mm would accurately predict susceptibility to teicoplanin. Only one minor discrepancy was observed with the moderately susceptible staphylococcus, which had an MIC of 8.0 jg/ml but was susceptible with all three teicoplanin disk potencies. DISCUSSION Teicoplanin and vancomycin are two glycopeptide antibiotics with similar spectrums of activity, which are limited to gram-positive microorganisms. However, teicoplanin is more active than vancomycin. The activity of teicoplanin against the enterococci, methicillin-resistant staphylococci, and the JK group of corynebacteria is particularly noteworthy, since those pathogens present serious therapeutic problems. Both glycopeptide antibiotics differ from fusidic acid and coumermycin, two other drugs with spectrums of activity largely limited to gram-positive bacteria. Bacterial resistance among normally susceptible species has not been documented.
Using agar dilution procedures, other investigators (1, 2, 10) have found that teicoplanin is only slightly more active than vancomycin. Bauernfeind and Petermuller (1) documented the fact that teicoplanin agar dilution MICs were significantly greater than those observed with broth microdilution tests (up to 32-fold higher). Our teicoplanin microdilution MICs were four-to eightfold lower than those previously reported with agar dilution procedures. However, our vancomycin microdilution MICs were essentially comparable to those reported in the previously cited studies. With either testing procedure, teicoplanin was more active than vancomycin; the methodology only influenced the magnitudes of the differences between the two drugs.
The unique pharmacokinetic properties of teicoplanin distinguish it from vancomycin (10, 11) . Peak levels in serum are similar to those observed with vancomycin, but the elimination half-life of teicoplanin is extremely prolonged, i.e., in excess of 40 h (10, 11) . With daily intravenous or intramusuclar injection, the level in serum should always exceed 2.0 jig/ml. At half the dosing interval (12 h), levels in serum should exceed 4.0 jig/ml. For that reason, an MIC breakpoint of .4.0 jig/ml for the susceptible category seems to be reasonably conservative. In fact, all of our susceptible strains were inhibited by .2.0 jig/ml in a microdilution test system. also be applied to tests with 30-,ug teicoplanin disks, in spite of the fact that teicoplanin appears to diffuse much more slowly through the agar medium.
In the absence of gram-positive cocci that are truly resistant to either glycopeptide, routine susceptibility tests are not currently necessary. One could predict susceptibility to both drugs without doing any in vitro study, with a >99% predictive value. With the recommended interpretive breakpoints, both 30-tLg disks performed with a >99% predictive value. One Staphylococcus sp. was moderately susceptible to teicoplanin but susceptible to vancomycin, and one strain of Streptococcus faecium was moderately susceptible to vancomycin but susceptible to teicoplanin. When retested, the MICs for both of those strains did not change. It is difficult to determine whether those two aberrant strains were truly resistant, but they were both susceptible by the disk tests. With the exception of those two aberrant strains, all vancomycin-susceptible strains were also susceptible to teicoplanin, and all teicoplaninsusceptible strains were also susceptible to vancomycin. Either disk could be used for predicting susceptibility to the other drug. However, since no resistant clinical isolates are
